We welcome the announcement that the National Institute for Health and Care Excellence (NICE) has approved a new drug, Abaloparatide, for use by the NHS in England. It will be available to eligible patients within three months.
Abaloparatide increases bone density by stimulating the cells that make new bone and it has been recommended for patients at high risk of bone fractures. NICE estimates that it could benefit more than 14,000 women who have gone through menopause.
See the news article on the NICE website.